Valuation: Cybin

Market Cap 124Cr 87Cr 77Cr 72Cr 66Cr 8.38TCr 125.7Cr 874.37Cr 338.48Cr 4.27TCr 326.7Cr 319.61Cr 14TCr P/E 2027 *
-4.57x
P/E 2028 * -5.54x
Enterprise Value 76Cr 53Cr 47Cr 44Cr 40Cr 5.12TCr 77Cr 534.03Cr 206.73Cr 2.61TCr 199.53Cr 195.21Cr 8.37TCr EV / Sales 2027 *
-
EV / Sales 2028 * 60.4x
Free-Float
85.98%
Yield 2027 *
-
Yield 2028 * -
1 day-3.09%
1 week-5.40%
Current month-3.09%
1 month+2.67%
3 months+89.65%
6 months+138.68%
Current year+45.60%
1 week 11.63
Extreme 11.63
12.96
1 month 11.39
Extreme 11.39
15.15
Current year 3.76
Extreme 3.76
15.15
1 year 3.76
Extreme 3.76
15.15
3 years 3.76
Extreme 3.76
28.04
5 years 3.76
Extreme 3.76
89.49
10 years 3.76
Extreme 3.76
128.44
Manager TitleAgeSince
Chief Operating Officer 37 13/10/2016
Chief Executive Officer 53 03/08/2026
Chief Executive Officer 51 02/09/2025
Director TitleAgeSince
Chairman 51 05/11/2020
Director/Board Member 37 13/10/2016
Director/Board Member 65 05/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
21/09/26 Buy

Chief Executive Officer

1,00,000 0.1613%
21/09/26 Buy

Chief Executive Officer

1,00,000 0.1613%
17/09/26 Other

Chief Executive Officer

14,26,902 2.3020%
Change 5-day change 1-year change 3-year change Capi.($)
-3.09%-5.40%+99.16%-41.02% 87Cr
+4.16%+3.04%+49.37%+94.17% 7.44TCr
-1.12%-1.56%+24.40%+78.16% 5.93TCr
-0.29%-1.83%+3.02%+32.89% 4.71TCr
-3.02%-5.20%+27.94%+32.51% 4.29TCr
+0.31%+3.02%+348.95%+643.82% 4.41TCr
-1.96%-0.33%+7.04%+99.46% 4.08TCr
+3.32%+3.49%+10.10%+51.23% 3.08TCr
-3.03%+2.55%+29.16%+22.27% 2.93TCr
-4.86%-10.66%-26.27%+330.06% 2.37TCr
Average -0.96%-1.01%+57.29%+134.36% 3.93TCr
Weighted average by Cap. -0.18%-0.33%+57.91%+145.11%

Financials

2027 *2028 *
Net sales - 1.11Cr 77.67L 68.98L 64.51L 58.79L 75Cr 1.12Cr 7.8Cr 3.02Cr 38Cr 2.92Cr 2.85Cr 122.32Cr
Net income -26Cr -18Cr -16Cr -15Cr -14Cr -1.77TCr -26Cr -184.31Cr -71Cr -899.4Cr -69Cr -67Cr -2.89TCr -26Cr -18Cr -16Cr -15Cr -14Cr -1.77TCr -27Cr -184.49Cr -71Cr -900.27Cr -69Cr -67Cr -2.89TCr
Net Debt -48Cr -34Cr -30Cr -28Cr -26Cr -3.26TCr -49Cr -340.34Cr -131.75Cr -1.66TCr -127.16Cr -124.41Cr -5.33TCr -57Cr -40Cr -36Cr -33Cr -30Cr -3.86TCr -58Cr -402.68Cr -155.88Cr -1.96TCr -150.45Cr -147.19Cr -6.31TCr
Logo Cybin
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Employees
100
Date Price Change Volume
01/26/01 $11.91 -3.09% 13,28,306
30/26/30 $12.29 -3.23% 8,23,389
29/26/29 $12.70 +0.87% 9,72,657
28/26/28 $12.59 -0.16% 9,86,597
25/26/25 $12.61 +0.16% 8,05,810
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
16.97CAD
Average target price
56.76CAD
Spread / Average Target
+234.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HELP Stock